Gamow Labs
Gamow Labs builds AI systems that interpret whole-genome sequencing data, delivering ACMG-style clinical reports with confidence scores and treatment suggestions. The platform re-analyzes past cases against new literature and patient symptoms, and the company also develops AI agents that operate robotic wet labs to increase experimental throughput.
- Healthcare Technology
- Artificial Intelligence
- Digital Health
- AI Agents
- Biotechnology
- Robotics
- Data & Analytics
- Software Only
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Genome sequencing has become inexpensive, yet interpreting results remains slow, expensive, and dependent on scarce specialist expertise. Most hard cases still rely on manual analysis by analysts, counselors, and physicians, leaving many patients without timely or actionable diagnoses.
Solution
Gamow Labs provides an AI-native genomic interpretation agent that ingests a patient's whole genome alongside structured or unstructured clinical phenotype data. The agent weighs every variant against current evidence at machine scale, then returns an ACMG-style clinical report with a causative variant, confidence scores, auditable evidence, and a proposed treatment plan. It supports a living-diagnosis model in which past cases are automatically rechecked against fresh gene-disease literature, evolving patient symptoms, and updated variant annotations without re-sequencing. The platform is designed to generalize beyond academic medical centers so that universal whole-genome sequencing can deliver clinical answers for broader patient populations. The company also operates a robotic wet lab and develops agents that can run experiments and recover from equipment failures, increasing experimental throughput for biological research.
Target Audience
Primary customers are clinical genomics laboratories, hospitals, and health systems offering whole-genome sequencing, particularly those in neonatal intensive care units and pediatric genetics programs seeking scalable diagnostic support without dedicated on-staff geneticists. The company also targets frontier-model developers and laboratory automation companies as partners for its robotic lab agents.
Features
- AI-driven variant interpretation that evaluates all genomic variants against current evidence at high throughput
- ACMG-style reporting with confidence levels, auditable reasoning chains, and treatment-plan suggestions
- Living-diagnosis engine that re-interprets stored cases when new gene-disease links or variant classifications are published
- Dynamic phenotype integration that re-ranks variants as a patient's clinical picture evolves
- Robotic wet-lab automation with AI agents capable of diagnosing equipment errors and resuming interrupted experiments
- LabRobotBench, an in-silico simulation that evaluates frontier AI models on troubleshooting and executing wet-lab workflows
- Validated performance in a blinded study of 66 non-diagnostic alveolar capillary dysplasia cases, identifying molecular explanations for all known cases and solving two that had eluded human experts for years